An aberrantly low expression of CD34 on MPCs may occur in MDS [23], therefore two distinct gating strategies for MPCs were employed: one based on CD34 expression and the other on CD117 and CD33 expression. This evidence concerns the gene CD34 and myelodysplastic syndrome.